- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04463576
Drug Interactions in Hospital Information System. The PRoSIT System.. (PROSIT)
April 24, 2024 updated by: University Hospital, Bordeaux
Development, Validation and Impact of an Automatic Identification of Co-Prescription at Risk of Interactions in the Hospital Information System. The PRoSIT System.
The French Public Health strategy 2018-2022 aims to reduce inappropriate prescriptions, as potentially dangerous for individuals and collectively.
The reduction of co-prescriptions at Risk of Drug Interactions (RoDI) could decrease the prevalence of iatrogenic diseases, and increase the persistence of treatments with a growing efficacy of treatments, in particular in elderly populations.
A recent study conducted by our team showed that, in out-patient setting, 2.7% of co-prescriptions contains medications at RoDI of high degree of severity (object of a contra-indication or non-recommended).
Up today, there is no French experience concerning the identification of RoDI among the prescriptions performed at the end of a hospitalisation.
In France, the recent development of hospital data warehouses is a huge opportunity to develop a system that can identify efficiently co-prescriptions at RoDI and provide feedback directly to prescribers in order to reduce their frequency in hospital context.
The primary objective of this study is to evaluate the capacity of a system, called PRoSIT system, to automatically identify the RoDI of high level of severity at hospital discharge.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a national multicentre study structured in three phases.
- Phase 1. Development of the PRoSIT tool and interface. The PRoSIT tool will identify all the drugs listed in the hospital discharge prescriptions and will automatically search for IMPs, through the thesaurus of interaction of the French Agency of Drug Safety. The PRoSIT interface will allow navigation from aggregated information to source documents. This module will include a never event alert system, will be updated daily, and will be available on demand for the prescribers and referent pharmacists.
- Phase 2. Evaluation of the PRoSIT system performance. This phase will validate the ability of the PRoSIT tool to identify severe IMPs among the drugs listed in the hospital discharge prescriptions. The performance of the PRoSIT system will be evaluated in comparison to a gold standard based of experts opinion of a representative sample of hospital discharge prescriptions in patients aged 65 years or over, hospitalized or seen in consultations in the centres of cardiology, internal medicine or neurology of three University Hospitals (Bordeaux, Rennes and HEGP).
- Phase 3. Impact of PRoSIT on the care organization. Once validated, the PRoSIT tool will be used and evaluated at Bordeaux University Hospital. Its use will be accompanied by a presentation to users (clinicians and hospital pharmacists) as well as though regular feedbacks. A qualitative analysis will allow evaluation of the appropriation of the PRoSIT system and its impact on the organization of care. Semi-structured interviews with practitioners and pharmacists, and a series of observations of the PRoSIT feedback will be conducted, in order to measure the collective dimension of the observed changes in practices.
Study Type
Observational
Enrollment (Estimated)
5769
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Louis LETINIER, Dr
- Phone Number: +33 5 57 57 15 60
- Email: louis.letinier@chu-bordeaux.fr
Study Contact Backup
- Name: Francesco SALVO, Pr
- Phone Number: +33 5 57 57 15 60
- Email: francesco.salvo@u-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Hopital Pellegrin
-
Contact:
- Francesco SALVO, Pr
- Email: francesco.salvo@u-bordeaux.fr
-
Paris, France, 75015
- Hôpital Européen George Pompidou
-
Contact:
- Anita BURGUN, Pr
- Phone Number: +33 1 44 27 63 93
- Email: anita.burgun@aphp.fr
-
Rennes, France, 35033
- CHU de Rennes
-
Contact:
- Marc CUGGIA, Pr
- Phone Number: +33 2 99 28 25 55
- Email: marc.cuggia@univ-rennes1.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients aged 65 years or older AND in the cardiology, internal medicine and neurology departments of University Hospital of Bordeaux, University Hospital of Rennes, and Georges Pompidou European Hospital recorded between June 1, 2018 and June 1, 2019.
Description
Inclusion Criteria:
- A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected if they concern: patients aged 65 years or older AND in the cardiology, internal medicine and neurology departments of University Hospital of Bordeaux, University Hospital of Rennes, and Georges Pompidou European Hospital recorded between June 1, 2018 and June 1, 2019.
- For the evaluation of the determinants of acceptability and effectiveness of the intervention: a group of 18 hospital practitioners and three hospital pharmacists from the concerned departments of Bordeaux University Hospital will be included.
- For phase 3, all hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions only of the Bordeaux University Hospital will be used to analyse the impact of the feedback.
Exclusion Criteria:
• Hospital discharge prescriptions not corresponding to inclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Experimental
A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected.
|
All hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions of the Bordeaux and Rennes University Hospital and Georges Pompidou European Hospital will be recorded between June 1, 2018 and June 1, 2019.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of automatic identification of co-prescription at Risk of Drug Interactions (RoDI)
Time Frame: 36 months after inclusion
|
Thanks to PRoSIT tool and interface development.
The PRoSIT tool will identify all the drugs listed in the hospital discharge prescriptions and will automatically search for IMPs, through the thesaurus of interaction of the French Agency of Drug Safety.
|
36 months after inclusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Florence FRANCIS, Dr, USMR
- Principal Investigator: Francesco SALVO, Pr, University Hospital, Bordeaux
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
July 3, 2020
First Submitted That Met QC Criteria
July 3, 2020
First Posted (Actual)
July 9, 2020
Study Record Updates
Last Update Posted (Actual)
April 25, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CHUBX 2019/62
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction
-
Hutchison Medipharma LimitedCompletedFood-drug Interaction | Drug InteractionUnited States
-
University of Southern CaliforniaRecruitingDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingDrug Drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Enrolling by invitationDrug-drug InteractionKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug Drug InteractionKorea, Republic of
-
ItalfarmacoCompletedDrug-Drug InteractionPortugal
-
Aurinia Pharmaceuticals Inc.CompletedDrug-drug InteractionUnited States
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Nanjing Yoko Biomedical Co., Ltd.CompletedDrug-drug InteractionChina
Clinical Trials on Discharge Prescription
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Unknown
-
Barretos Cancer HospitalCompleted
-
Oregon Health and Science UniversityLaura and John Arnold FoundationCompleted
-
Ward of the 21st CenturyCanadian Institutes of Health Research (CIHR); Alberta Health services; University...CompletedOther Diagnoses, Comorbidities, and ComplicationsCanada
-
Kamil NovobílskýCompletedCoronary Artery Disease | Primary Percutaneous Coronary Intervention | Early Discharge | Acute Myocardial Infarction With ST-segment ElevationCzechia
-
Ottawa Heart Institute Research CorporationRecruitingCoronary Artery DiseaseCanada
-
Hospital de Clinicas de Porto AlegreUnknown
-
Fundació Institut de Recerca de l'Hospital de la...UnknownMyocardial InfarctionSpain
-
University at BuffaloNational Center for Advancing Translational Sciences (NCATS)CompletedBrain Injury | ConcussionUnited States
-
Bartın UnıversityCompletedFever | Child, OnlyTurkey